OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 500,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were bought at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the completion of the acquisition, the chief executive officer now owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The shares were bought at an average cost of $1.53 per share, with a total value of $304,580.16.
- On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.59 per share, for a total transaction of $159,000.00.
- On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00.
- On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was purchased at an average price of $1.50 per share, for a total transaction of $420,274.50.
OPKO Health Trading Up 1.9 %
Elon Spotted at Weird Facility in Memphis?
From Paradigm Press | Ad
What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date.
Because now, he is targeting the world’s most powerful technology…
And doing it bigger – and better – than everyone else.
Go here to see what Elon is planning.
NASDAQ:OPK opened at $1.59 on Thursday. The business's 50-day moving average is $1.53 and its two-hundred day moving average is $1.47. The firm has a market capitalization of $1.09 billion, a PE ratio of -8.37 and a beta of 1.62. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.
Analyst Ratings Changes
A number of research firms have recently commented on OPK. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler restated an "overweight" rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th.
Get Our Latest Stock Analysis on OPKO Health
Institutional Investors Weigh In On OPKO Health
Large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company's stock worth $536,000 after acquiring an additional 17,671 shares in the last quarter. Comerica Bank raised its stake in shares of OPKO Health by 125.0% during the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company's stock valued at $108,000 after purchasing an additional 50,000 shares during the period. CIBC Asset Management Inc raised its stake in shares of OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 8,978 shares during the period. PFG Investments LLC lifted its position in shares of OPKO Health by 2.5% during the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company's stock worth $1,201,000 after purchasing an additional 23,700 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of OPKO Health in the second quarter valued at $112,000. Institutional investors and hedge funds own 64.63% of the company's stock.
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
